8-K: Alphatec Reports Strong 2025 Revenue Growth, Positive 2026 Outlook

Alphatec Holdings, Inc. announced preliminary unaudited financial results for 2025, showing significant revenue growth, and provided a positive financial outlook for 2026, alongside acquiring exclusive distribution rights for a next-generation biologic.

Summary

• Preliminary unaudited full-year 2025 total revenue grew approximately 25% to a range of $763.4 million to $764.4 million.
• Full-year 2025 surgical revenue grew 26% to a range of $686.3 million to $687.0 million, driven by 24% surgical volume growth and 2% average revenue per procedure growth.
• Re-affirmed full-year 2025 adjusted EBITDA guidance of $91 million.
• Cash balance as of December 31, 2025, approximated $161 million, with expected fourth-quarter free cash flow in the range of $6 million to $8 million.
• Anticipates full-year 2026 total revenue of $890 million, reflecting approximately 17% growth compared to 2025.
• The 2026 outlook includes expected surgical revenue of approximately $805 million and EOS revenue of approximately $85 million.
• Expects 2026 adjusted EBITDA of approximately $130 million, contributing to an expected $20 million of free cash flow.
• Acquired exclusive U.S. distribution rights for Theradaptives OsteoAdapt, a next-generation rhBMP-2 biologic solution, which is currently in Phase II clinical trials for spinal fusion.
• Granted 67,643 restricted stock units (RSUs) to 16 new employees (not executive officers) as inducement awards, vesting over four years.

Sentiment

Score: 8

Explanation: The filing presents strong preliminary financial results for 2025, re-affirms positive EBITDA guidance, and provides an optimistic outlook for 2026 with significant revenue and EBITDA growth. The strategic acquisition of exclusive distribution rights for a next-generation biologic further enhances future growth prospects. The only minor caveat is the preliminary nature of the results, which is standard for such announcements.

Positives

• Strong preliminary full-year 2025 total revenue growth of approximately 25% to $763.4M-$764.4M.
• Significant full-year 2025 surgical revenue growth of 26%, driven by 24% volume growth and 2% average revenue per procedure growth.
• Re-affirmed full-year 2025 adjusted EBITDA guidance of $91 million, indicating strong leverage.
• Positive cash balance of approximately $161 million as of December 31, 2025, and expected Q4 free cash flow of $6M-$8M.
• Robust 2026 financial outlook with anticipated total revenue of $890 million (17% growth) and adjusted EBITDA of $130 million.
• Acquisition of exclusive U.S. distribution rights for OsteoAdapt, a next-generation rhBMP-2 biologic, expected to expand procedural offerings and address market concentration.
• Management highlights achieving "results at scale that have not been seen in our industry."

Negatives

• Preliminary financial results are unaudited and subject to adjustment, which may be material, during the final closing process.

Risks

• Uncertainty of success in developing new products or products currently in the pipeline.
• Uncertainties in the ability to execute upon the strategic operating plan.
• Uncertainties regarding the ability to successfully license or acquire new products, and the commercial success of such products.
• Failure to achieve acceptance of products by the surgeon community.
• Failure to obtain FDA or other regulatory clearance or approval or unexpected or prolonged delays in the process.
• Continuation of favorable third-party reimbursement.
• Unanticipated expenses or liabilities or other adverse events affecting cash flow or the ability to achieve profitability.
• Uncertainty of additional funding and the form of such funding.
• Product liability exposure.
• An unsuccessful outcome in any litigation.
• Patent infringement claims.
• Claims related to intellectual property.
• Ability to meet financial obligations.

Future Outlook

The company anticipates full-year 2026 total revenue of $890 million, representing approximately 17% growth over 2025, with surgical revenue of $805 million and EOS revenue of $85 million. Adjusted EBITDA is projected to reach $130 million, contributing to an expected $20 million in free cash flow for 2026.

Management Comments

• "I'm proud of the entire ATEC Family for delivering a very strong 2025."
• "We are achieving results at scale that have not been seen in our industry."
• "This shared success is no accident; we have amassed an unparalleled collection of spine know-how and clinical curiosity, and are relentlessly driven to improve surgery through a disciplined focus on procedural ecosystems, supported by data and informatics."
• "We have many growth catalysts ahead, and with a scalable infrastructure already in place, ATEC is positioned to shape the future of spine care for years to come."

Industry Context

The announcement highlights Alphatec's continued strong growth in the spine surgery market, driven by surgeon adoption and procedural innovation. The acquisition of exclusive distribution rights for OsteoAdapt, a next-generation rhBMP-2 biologic, positions the company to address a long-standing market concentration challenge in a key segment of spinal fusion, potentially disrupting the existing landscape dominated by legacy biologics.

Comparison to Industry Standards

• Management claims to be "achieving results at scale that have not been seen in our industry," suggesting outperformance relative to competitors in the spine surgery sector.
• The OsteoAdapt acquisition aims to address the "long-standing challenge of market concentration of rhBMP-2," indicating a strategic move to compete more effectively against established players in the biologic market for spinal fusion.
• The company's focus on "procedural ecosystems, supported by data and informatics" aligns with broader industry trends towards integrated solutions and data-driven surgical improvements.

Management Changes

Stakeholder Impact

• Shareholders: Positive impact due to strong financial performance, positive outlook, and strategic product expansion, potentially leading to increased share value.
• Employees: Positive impact for 16 new employees receiving inducement awards, and overall positive sentiment from strong company performance.
• Customers (Surgeons): Enhanced product offerings with the addition of OsteoAdapt, potentially improving surgical outcomes and expanding procedural options.

Next Steps

• Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026.
• Report fourth quarter and full-year 2025 financial results on February 24, 2026, after market close.
• Host a live webcast for Q4 and full-year 2025 earnings on February 24, 2026, at 1:30 p.m. PT / 4:30 p.m. ET.

Key Dates

Recommendation

The company has demonstrated robust preliminary financial performance for 2025, exceeding expectations with significant revenue growth and re-affirmed adjusted EBITDA. The 2026 outlook projects continued strong double-digit revenue growth and substantial adjusted EBITDA expansion, indicating a clear path to profitability and cash flow generation. The strategic acquisition of exclusive distribution rights for OsteoAdapt, a next-generation rhBMP-2 biologic, is a significant catalyst, addressing a concentrated market and expanding the company's procedural offerings. Management's confidence in achieving 'results at scale not seen in our industry' further underscores the strong operational momentum and strategic positioning. While results are preliminary, the consistent positive trajectory and strategic moves warrant a strong buy recommendation for long-term investors.

Keywords

Alphatec Holdings, ATEC, Spine Surgery, Medical Devices, Financial Results, Revenue Growth, EBITDA, Free Cash Flow, OsteoAdapt, rhBMP-2, Biologic, SEC Filing, 8-K, Preliminary Results, Financial Outlook, Surgical Revenue, EOS Revenue, Nasdaq